GLP-1 microdosing — prescribing semaglutide or tirzepatide at a fraction of the labelled dose, usually for “metabolic health”, “longevity” or gentle maintenance rather than obesity — has become one of the fastest-spreading offers in wellness.
It is worth separating three different things that get blended together: dose titration, off-label prescribing, and marketing a protocol the evidence does not support.
What it usually means in practice
Approved GLP-1 products have defined titration schedules that start low and step up to a therapeutic dose. Starting low is not microdosing — it is the label.
Microdosing as marketed generally means deliberately staying below therapeutic dosing indefinitely, often in patients who do not meet the approved indication, and frequently promoted for benefits other than weight reduction.
Where the ground is firm and where it is not
| Practice | Standing |
|---|---|
| Titrating per label | Ordinary prescribing |
| Holding a lower dose because of tolerability, documented | Reasonable clinical judgment |
| Off-label prescribing after evaluation, with rationale recorded | Lawful medical practice in appropriate circumstances |
| Advertising a sub-therapeutic protocol for longevity or metabolic health | Marketing an unapproved use — a different question entirely |
| Prescribing to patients who plainly do not meet criteria | Hard to defend clinically or commercially |
The line most operators miss: a physician may exercise judgment about dose. A website may not promote a use the product is not approved for. Those are separate standards, and the second one is where the exposure sits.
The evidence question
Trials establishing efficacy and safety studied specific populations at specific doses. A protocol that deliberately stays below those doses, in patients unlike those studied, for endpoints that were not measured, is not supported by the trial data — it is an extrapolation.
That does not make it impossible to justify for an individual patient. It does make it impossible to justify as an advertised programme.
The sourcing trap underneath it
Microdosing protocols frequently rely on compounded product, because small or unusual doses are awkward with approved pens.
Since the semaglutide and tirzepatide shortages resolved and the enforcement grace periods expired, broad compounding of these drugs is no longer available as a shortage response. A programme designed around cheap compounded supply may not have a lawful supply chain at all — which is a bigger problem than the dosing debate.
The safety point people skip
A sub-therapeutic dose is not automatically a safer dose. It is a dose with an unstudied benefit profile and largely the same contraindications. Personal and family history of medullary thyroid carcinoma, MEN 2, pancreatitis history, pregnancy — none of that becomes less relevant because the dose is small.
Evaluation requirements do not scale down with the dose.
If you offer it
- Evaluate properly and document why this patient, this dose, this rationale
- Do not advertise the protocol as an approved or evidence-backed programme
- Screen contraindications exactly as you would at full dose
- Know and document your supply basis
- Monitor, and be prepared to stop
- Say plainly that it is off-label and that individual results vary
The strategic view
Microdosing is popular partly because it lowers the cost per patient and widens the eligible pool. Those are business advantages, not clinical findings, and a programme built on them will read that way to anyone reviewing it.
The clinics that will still be running this line in three years are the ones that treated it as prescribing with judgment, not as a product tier.
How MDside handles it
Our providers make dosing decisions patient by patient with the rationale documented, protocols reflect current labelling and supply reality, and we do not permit marketing that presents sub-therapeutic dosing as an approved or proven programme.
See what is included, or read about what changed after the GLP-1 shortages ended.
Frequently asked questions
Is GLP-1 microdosing legal?
Off-label prescribing is lawful medical practice in appropriate circumstances, decided patient by patient. Advertising a sub-therapeutic protocol for an unapproved purpose is a separate question and carries real risk.
Is a lower dose safer?
Not automatically. Contraindications and the need for evaluation do not change with dose, and the benefit profile at sub-therapeutic dosing is not well studied.
Can I use compounded product for microdosing?
Broad shortage-based compounding of semaglutide and tirzepatide has ended. Confirm the specific lawful basis for any compounded supply before building a programme on it.
Can I market it for longevity?
That promotes an unapproved use and is not supported by the trial evidence. Describe what you do clinically without advertising outcomes the data does not establish.
What should the record show?
Why this patient was evaluated as appropriate, why this dose was chosen, what was discussed about off-label status, and how the patient is being monitored.
General information, not medical or legal advice, and not a treatment recommendation. Confirm prescribing decisions with your medical director and marketing claims with healthcare counsel.